Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

Development Leadership Team in Place to Advance Voreloxin to Late-Stage

Trials Strategic Realignment Includes Workforce Reduction to Streamline Operations

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a corporate realignment to focus on the development of the company's lead oncology product candidate, voreloxin (formerly SNS-595). In conjunction with this strategic restructuring, Sunesis expanded the company's late-stage development leadership team and announced a workforce reduction of approximately 60 percent, including the winding down of its research activities. These changes are intended to concentrate the company's financial and human resources on the strongest path to potential near-term value creation for the company's stockholders.

"Based on the promising clinical data achieved to date, we have made a strategic decision to focus the organization on generating critical clinical data by advancing our lead compound, voreloxin, into late-stage trials in the acute myeloid leukemia and ovarian cancer indications," said Daniel Swisher, Sunesis' Chief Executive Officer. "Late-stage development requires increased focus of our resources. We are also expanding and strengthening our development team with the additions of Drs. Steve Ketchum and Mary Bolton. Their extensive product development and regulatory expertise and track records of successful FDA submissions in a breadth of therapeutic areas will support our plan to advance voreloxin through late-stage trials."

Steven B. Ketchum, Ph.D., has been appointed as Senior Vice President, Research and Development and Mary G. Bolton, M.D., Ph.D., as Vice President,
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/9/2014)... was told she had an aneurysm, she figured an invasive ... "I was devastated," said Wakulich, who is 56 years old ... a serious diagnosis. Then I met Dr. Bernard Bendok who ... invasive procedure. It was something I didn,t even know was ... U.S. clinical trial to evaluate the safety and effectiveness of ...
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... NEW YORK (July 8, 2014) Researchers from ... College of Medicine of Yeshiva University will present ... being held July 12 July 17 in Copenhagen, ... triggers that could prompt transition from cognitive normality to ... of the Einstein Aging Study , established in ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... new set of strategies released today by the Commonwealth ... dramatically improve how the U.S. health care system serves ... or members of racial and ethnic minority groups. ... Framework to Achieve High Performance Health Care for Vulnerable ...
... A new study finds liver cancer incidence rates continue to increase ... and are decreasing in some of the highest risk countries of ... as high as those in Africa and more than four times ... published in an upcoming issue of Cancer Epidemiology Biomarkers and ...
... diagnosing sinusitis is presented in a new thesis from Lund University. ... and the costs of the disease to society. Sinusitis ... and a chronic form. In Europe, over nine per cent of ... the thesis is Pernilla Sahlstrand Johnson, a PhD student and ear, ...
... HealthDay Reporter , THURSDAY, Oct. 6 (HealthDay News) -- Indoor tanning ... previously believed. New research published online Oct. 6 in the ... of ultraviolet rays used in tanning beds -- UVA1 -- may ... to the cancer-causing changes caused by UV rays. ...
... marijuana plant could prevent the onset of pain associated ... cancer patients, according to researchers at Temple University,s School ... Prevents the Development of Cold and,Mechanical Allodynia in Paclitaxel-Treated ... Analgesia . The researchers developed animal models and ...
... 6 October, 2011, Bad Gastein, Austria Globally, people believe that ... health as do health care providers, according to the Edelman ... believe that their friends and family have the most impact ... than a third (36%) believe friends and family have the ...
Cached Medicine News:Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 2Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 4Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 5Health News:Study finds liver cancer increasing in low risk countries, decreasing in high risk countries 2Health News:New method to diagnose sinusitis could reduce use of antibiotics 2Health News:Tanning Beds May Be Even Riskier Than Thought 2Health News:Tanning Beds May Be Even Riskier Than Thought 3Health News:Marijuana component could ease pain from chemotherapy drugs 2Health News:Friends and family as responsible as health-care professionals for personal health, global survey 2
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
... High Throughput Screening (HTS), Analyst HT ... HTS by sharing all the detection ... AD, fluorescence intensity, fluorescence polarization, time-resolved ... seamless integration into robotic environments, including ...
... Designed for Ultra High Throughput ... multimode assay detection performance. Allows for ... from assay development by sharing all ... and HT, fluorescence intensity, fluorescence polarization, ...
Medicine Products: